Adragos Hub

Selecting a Contract Development and Manufacturing Organisation for High-Potency Active Pharmaceutical Ingredient small molecule programmes requires a structured, evidence-based evaluation. The critical criteria are: validated Occupational Exposure Band 5 containment, Good Manufacturing Practice certification that explicitly covers the high-potency suite, […]

Pharmaceutical and biotech companies selecting sterile injectable contract development and manufacturing organisation (CDMO) services in Europe must evaluate partners across seven critical dimensions: programme-fit and technical capability, regulatory standing and Good Manufacturing Practice (GMP) certifications, Chemistry, Manufacturing and Controls (CMC) […]

April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed […]

A Strategic Guide to Navigating Early-Stage Fill-Finish for Biologics Optimising early-stage fill-finish for biologics begins at a point where resources are constrained, knowledge is incomplete, and regulatory scrutiny is intense. The central task is to convert a promising molecule into […]

For pharma and biotech companies, selecting a sterile manufacturing partner is about more than equipment or capacity alone. It is about choosing a site that can combine reliable PFS manufacturing, sterile vial production, quality systems and operational support in a way that enables […]

Munich, April 1, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile […]